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Antenatal 
corticosteroids to 
reduce preterm deaths 
in low-income settings
In their Comment (April issue),1 
Kishwar Azad and Anthony Costello 
raise questions that should be answered 
before antenatal corticosteroid treat-
ment is scaled up to reduce pre term 
deaths in low-income countries. We 
share their concerns about the unknown 
overall effect of this treatment on 
mortality and potential safety issues in 
the mother. To answer these questions, 
we have initiated the Antenatal 
Corticosteroids Trial2 to assess whether 
or not a multifaceted intervention 
to increase the use of antenatal 
corticosteroids reduces neonatal 
mortality at 28 days of age, and 
maternal morbidity due to infections. 
Enrolment has been completed and 
data from more than 90 000 births have 
been collected.
We disagree with Azad and Costello’s 
comment about the eﬀ ect of antenatal 
corticosteroid treatment on respiratory 
distress in infants at 34 weeks’ 
gestation. This statement is based on 
a subgroup analysis from a systematic 
review.3 However, the same review 
presents data showing a decreased 
risk of respiratory distress syndrome 
in infants with first dose of cortico-
steroids administered to mothers 
at 33–35 weeks’ gestation (relative 
risk [RR] 0·53, 95% CI 0·31–0·91), 
and a non-signiﬁ cant decrease in the 
risk of respiratory distress in infants 
(0·61, 0·11–3·26) with first dose at 
35–37 weeks’ gestation. The ﬁ ndings 
suggest a reduction in respiratory 
distress syndrome is present according 
to gestational age at ﬁ rst delivery of 
corticosteroids.3 
Prevention of respiratory distress 
syndrome in infants born at 
33–36 weeks’ gestation without access 
to specialised high-quality level 2 care 
might create a substantial health-care 
burden in low-income countries. The 
Antenatal Corticosteroids Trial2 will 
assess the administration of steroids 
to mothers up to 36 weeks’ gestation. 
Data from this trial will be available in 
the second half of 2014. We hope that 
several of the concerns expressed in 
the Comment by Azad and Costello 
will be addressed. 
We declare that we have no competing interests.
Copyright © Althabe et al. Open Access article 
distributed under the terms of CC BY-NC-ND. 
Fernando Althabe, José M Belizán, 
Pierre Buekens, *Elizabeth M McClure, 
Marion Koso-thomas, on behalf of the 
NICHD’s Global Network for Women’s 
and Children’s Health Research ACT 
Trial Steering Committee
mcclure@rti.org
Institute for Clinical Eﬀ ectiveness and Health Policy, 
Buenos Aires, Argentina (FA, JMB); Tulane School of 
Public Health and Tropical Medicine, New Orleans, 
LA, USA (PB); RTI International, 3040 Cornwallis 
Drive, Durham, NC, 27709, USA (EMM); Eunice 
Kennedy Shriver National Institute of Child Health 
and Human Development, Rockville MD, USA (MK-T)
1 Azad K, Costello A. Extreme caution is needed 
before scale-up of antenatal corticosteroids to 
reduce preterm deaths in low-income settings. 
Lancet Glob Health 2014; 2: e191–92. 
2 Althabe F, Belizán JM, Mazzoni A, et al. Antenatal 
corticosteroids trial in preterm births to increase 
neonatal survival in developing countries: study 
protocol. Reprod Health 2012; 9: 22.
3 Roberts D, Dalziel SR. Antenatal corticosteroids 
for accelerating fetal lung maturation for 
women at risk of preterm birth. 
Cochrane Database Syst Rev 2006; 3: CD004454.
